Samrat Pharmachem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022
For the full year, sales was INR 2,218.12 million compared to INR 1,790.18 million a year ago. Revenue was INR 2,223.63 million compared to INR 1,794.81 million a year ago. Net income was INR 171.85 million compared to INR 53.33 million a year ago. Basic earnings per share from continuing operations was INR 55.62 compared to INR 17.26 a year ago. Diluted earnings per share from continuing operations was INR 55.62 compared to INR 17.26 a year ago.